Calmark gets a patent, regarding methodology for LDH, approved in Vietnam

Calmark gets a patent, regarding methodology for LDH, approved in Vietnam

Pressmeddelanden
Press releases
The Ministry of Science and Technology in Vietnam has today approved Calmark's patent application for "Test systems for the determination of hypoxia-induced cellular injury". The patent is part of Calmark's patent family regarding the methodology around the biomarker LDH and is valid until 2030.

Lactate Dehydrogenase (LDH) is a biomarker that can detect if the child has had oxygen deficiency during childbirth. Calmark has worked with science research and development of this biomarker for many years. Therefore, the protection of intellectual property rights is central to Calmark's business.

Calmark develops a point-of-care (POC) diagnostic instrument, which consists of a reader and single-use tests, that detects biomarkers in the blood of newborns. Lactate dehydrogenase is one of the biomarkers expected to be launched in 2020, in Vietnam among other countries.

"The work on patents and intellectual property rights is central to Calmark. We have a close and fruitful cooperation since many years with Hynell Intellectual Property AB that helps us with these registrations. Another patent granted in Vietnam is very good news, since Vietnam is a priority market for the launch”, says CEO Anna Söderlund.